Table 1 Key clinical data

Projected PFS curve based on Log-logistic distribution in the chemotherapy arm

Shape = 2.075

Scale = 7.524

-

-

Projected OS curve based on Weibull distribution in the chemotherapy arm

Shape = 1.248

Scale = 25.801

-

-

Hazard ratio of cemiplimab plus chemotherapy vs. chemotherapy arm for PFS

0.56

0.44 – 0.7

Lognormal

Hazard ratio of cemiplimab plus chemotherapy vs. chemotherapy arm for OS

0.71

0.53 – 0.93

Lognormal

Grade ≥ 3 AEs in the chemotherapy arm

Incidence

Range

Distribution

Neutropenia

5.88%

4.41% to 7.35%

Beta

Anemia

6.54%

4.91% to 8.18%

Beta

Thrombocytopenia

1.31%

0.98% to 1.64%

Beta

Grade ≥ 3 AEs in the cemiplimab plus chemotherapy arm

Neutropenia

5.77%

4.33% to 7.21%

Beta

Anemia

9.94%

7.46% to 12.43%

Beta

Thrombocytopenia

2.56%

1.92% to 3.2%

Beta